The Oncology Institute, Inc. (NASDAQ:TOI) Sees Large Growth in Short Interest

The Oncology Institute, Inc. (NASDAQ:TOI) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 324,100 shares, an increase of 86.8% from the December 31st total of 173,500 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.9% of the company’s stock are sold short.

Oncology Institute Stock Performance

Shares of TOI traded down $0.01 during trading hours on Friday, reaching $1.00. 1,568,685 shares of the company traded hands, compared to its average volume of 986,129. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49. The stock’s fifty day moving average is $0.34 and its 200 day moving average is $0.35. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.20. The stock has a market cap of $75.56 million, a P/E ratio of -1.28 and a beta of 0.13.

Insider Transactions at Oncology Institute

In other Oncology Institute news, Director Brad Hively bought 250,000 shares of the stock in a transaction on Tuesday, November 26th. The shares were purchased at an average price of $0.17 per share, with a total value of $42,500.00. Following the acquisition, the director now directly owns 616,753 shares of the company’s stock, valued at $104,848.01. This represents a 68.17 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 9.50% of the stock is currently owned by company insiders.

Institutional Trading of Oncology Institute

An institutional investor recently raised its position in Oncology Institute stock. HighTower Advisors LLC lifted its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,362 shares of the company’s stock after purchasing an additional 53,382 shares during the quarter. HighTower Advisors LLC owned 0.11% of Oncology Institute worth $27,000 at the end of the most recent reporting period. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.